Compare · MRAI vs PGNY
MRAI vs PGNY
Side-by-side comparison of Marpai Inc. (MRAI) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRAI and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $2.14B, about 49.1x MRAI ($43.5M).
- PGNY has hit the wire 5 times in the past 4 weeks while MRAI has been quiet.
- PGNY has more recent analyst coverage (25 ratings vs 0 for MRAI).
- Company
- Marpai Inc.
- Progyny Inc.
- Price
- $0.92-55.67%
- $26.88-2.06%
- Market cap
- $43.5M
- $2.14B
- 1M return
- -
- -0.43%
- 1Y return
- -
- +25.94%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Marpai Inc.
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market. It also offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. The company was incorporated in 2021 and is based in Tampa, Florida.
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest MRAI
- Marpai Expands Relationship with Claritev to Help Reduce Healthcare Costs for Employer Clients
- Marpai Reports Second Quarter 2026 Financial Results
- New insider Mitchell Calvin Steven claimed ownership of 750,000 shares (SEC Form 3)
- SEC Form 10-Q filed by Marpai Inc.
- Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Marpai Announces $12 Million Private Placement led by Mitchell Companies
- Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Marpai Inc. Announces Debt Restructuring Agreements with JGB Capital and AXA, Reducing Debt Service by $26.4 Million Through 2027 and Enhances Near term Liquidity
- Director Eitan Yaron returned 50,000 shares to the company and was granted 175,000 shares, decreasing direct ownership by 4% to 1,224,073 units (SEC Form 4)
- Chief Financial Officer Johnson Steve Andrew was granted 125,000 shares and bought $682 worth of shares (1,100 units at $0.62), increasing direct ownership by 14% to 1,024,192 units (SEC Form 4)
Latest PGNY
- SEC Form 4 filed by Progyny Inc.
- Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting
- Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics
- EVP, GC Swartz Allison sold $101,868 worth of shares (3,903 units at $26.10) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 75,816 units (SEC Form 4)
- Chief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,009 units (SEC Form 4) to cover taxes
- Amendment: Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $311,858 worth of shares (11,500 units at $27.12) (SEC Form 4)
- Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $321,358 worth of shares (11,500 units at $27.94) (SEC Form 4)
- SEC Form 144 filed by Progyny Inc.
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 806,111 units (SEC Form 4) to satisfy tax liability
- EVP, GC Swartz Allison covered exercise/tax liability with 1,307 shares, decreasing direct ownership by 2% to 79,719 units (SEC Form 4) (withholding tax)